HSIRI THERAPEUTICS
Biotech · Private
Sideromycin antibiotic conjugates—small-molecule therapeutics that link siderophores to antibiotics to target gram-negative bacteria like Pseudomonas aeruginosa and Acinetobacter baumannii
hsiritherapeutics.com →- Grants
- $404K
- 2 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 11
- 1 granted · 10 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20162017
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Structural Modification of Daptomycin to Allow Anti-Pseudomonas Activity | $202,150 | |
| Federal grant | Department of Health and Human Services · Phase I · Structural Modification of Daptomycin to Allow Anti-Pseudomonas Activity | $202,150 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3322 | DNA SEQ 2, INC. | — | $1.2M |
| 3323 | Clasp Therapeutics | — | — |
| 3324 | Cgenetech, Inc. | — | — |
| 3325 | HSIRI THERAPEUTICS | — | — |
| 3326 | Grit Bio Inc | — | — |
| 3327 | SYNAPTEX, LLC | — | — |
| 3328 | SURFACE BIOADVANCES, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Benzyl Amine-containing 5,6-HETEROAROMATIC Compounds Useful Against Mycobacterial Infectionapplication
- A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME bc1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN AND CLOFAZIMINEapplication
- Antibacterial Sideromycinsgranted
- Synthetic Neoenactins And Combinations Of Neoenactins With Known Anti-fungal Agents With Enhanced Anti-fungal And Anti-dermatophyte Activityapplication
- Benzyl Amine-containing 5,6-HETEROAROMATIC Compounds Useful Against Mycobacterial Infectionapplication
- A Medicament For Treating Mycobacterial Infection Characterized By Combining A Cytochrome BC1 Inhibitor With Clarithromycin Or Azithromycin And Clofazimineapplication
- Benzyl Amine-containing 5,6-HETEROAROMATIC Compounds Useful Against Mycobacterial Infectionapplication
- MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME bc1 INHIBITOR WITH CLARITHROMYCIN AND CLOFAZIMINEapplication
- MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME bc1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCINapplication
- Cytochrome Bd Oxidase Inhibitors And Uses Thereofapplication
- A Medicament For Treating Mycobacterial Infection Characterized By Combining A Cytochrome BC1 Inhibitor With Clarithromycin Or Azithromycinapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.